Sei Investments Co. grew its stake in shares of Bioventus Inc. (NASDAQ:BVS - Free Report) by 160.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 289,648 shares of the company's stock after acquiring an additional 178,539 shares during the quarter. Sei Investments Co. owned about 0.35% of Bioventus worth $2,644,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Marshall Wace LLP grew its holdings in Bioventus by 0.4% in the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company's stock valued at $2,149,000 after purchasing an additional 1,281 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company's stock worth $211,000 after purchasing an additional 1,538 shares during the period. Mercer Global Advisors Inc. ADV raised its stake in Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company's stock worth $101,000 after purchasing an additional 1,887 shares during the period. Deutsche Bank AG boosted its holdings in shares of Bioventus by 8.2% in the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company's stock valued at $187,000 after purchasing an additional 1,908 shares during the last quarter. Finally, Engineers Gate Manager LP boosted its holdings in shares of Bioventus by 6.0% in the 4th quarter. Engineers Gate Manager LP now owns 68,889 shares of the company's stock valued at $513,000 after purchasing an additional 3,909 shares during the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several analysts have recently issued reports on BVS shares. Craig Hallum reissued a "buy" rating and set a $18.00 price objective on shares of Bioventus in a research note on Thursday. Barrington Research set a $18.00 target price on Bioventus in a research report on Thursday. Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 target price on shares of Bioventus in a report on Tuesday, June 16th. Finally, Weiss Ratings raised Bioventus from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Bioventus presently has an average rating of "Buy" and a consensus price target of $16.25.
Get Our Latest Stock Analysis on Bioventus
Bioventus Trading Up 1.1%
NASDAQ BVS opened at $14.13 on Friday. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 1.80 and a beta of 0.63. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.13 and a current ratio of 1.69. Bioventus Inc. has a one year low of $6.26 and a one year high of $15.89. The company's 50 day moving average price is $10.81 and its 200 day moving average price is $9.69.
Bioventus (NASDAQ:BVS - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The company had revenue of $153.21 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts predict that Bioventus Inc. will post 0.79 EPS for the current year.
About Bioventus
(
Free Report)
Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.
See Also
Want to see what other hedge funds are holding BVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioventus Inc. (NASDAQ:BVS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Bioventus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventus wasn't on the list.
While Bioventus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
